Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rigel Readies Tavalisse For Late-May Launch After FDA Approval

Apr 18 2018

• By Mandy Jackson

FDA approved background, 3D rendering, blue street sign

Related Content

RIGEL: 30 job cuts, new fostamatinib-led strategy

Sep 06 2013

Rigel Downsizes R&D To Ready Fostamatinib Commercial Effort

Sep 15 2016

Rigel Optimistic On Fostamatinib Despite Narrow Phase III Benefit

Aug 30 2016

Related Companies

Rigel Pharmaceuticals, Inc.

Amgen, Inc.

Novartis AG

AstraZeneca PLC

Additional Topics

Approvals Market Access Launches Reimbursement Commercial Immune Disorders BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.